Combination therapy for advanced lung cancer after PD-1 failure
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (Adibelimab and Famitinib) plus chemotherapy for people with advanced lung cancer that stopped responding to a PD-1 inhibitor. The goal is to see if this new triple therapy can help shrink tumors or slow down the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and willing to participate.
- Your lung cancer (stage IIIB or IV) has progressed after treatment with a PD-1 inhibitor (like Keytruda or Opdivo).
- You are able to perform daily activities without much help (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan.
- If you have brain metastases, they must have been treated and stable for at least 4 weeks.
- Your blood counts, liver, kidney, and clotting tests must be within certain limits.
- You agree to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a combination of two drugs—golidocitinib (a targeted pill) and sintilimab (an immunotherapy)—for people with advanced non-small cell lung cancer that has a high PD-L1 protein level. It may offer a new option if you haven't had immunotherapy before.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.